Marshall Wace’s Inovio Pharmaceuticals INO Stock Holding History

Marshall Wace’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,187	Closed	-$22.9K	–	3431
2026 Q1	$22.9K	Sell	13,187 -69,144	-84%	-$114K	﹤0.01%	3044
2025 Q4	$143K	Buy	+82,331	New	+$181K	﹤0.01%	2660
2024 Q2	–	Sell	-51,983	Closed	-$722K	–	2730
2024 Q1	$722K	Buy	+51,983	New	+$449K	﹤0.01%	1786
2021 Q2	–	Sell	-65,401	Closed	-$7.28M	–	2839
2021 Q1	$7.28M	Buy	+65,401	New	+$8.6M	0.03%	625

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Marshall Wace's INO Position: Q2 2026 in Review

Marshall Wace sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 13,187 shares — an estimated $22.9K sold.

Marshall Wace first reported a position in INO in Q1 2021 and held it in 4 quarters. The position peaked at $7.28M in Q1 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Marshall Wace reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 13,187 Inovio Pharmaceuticals shares in Q2 2026, an estimated $22.9K.
Marshall Wace first reported a position in Inovio Pharmaceuticals in Q1 2021 and held it in 4 quarters.
Marshall Wace's Inovio Pharmaceuticals position peaked at $7.28M in Q1 2021.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.